Addex Therapeutics (ADXN) Cash & Equivalents (2018 - 2026)

Addex Therapeutics has reported Cash & Equivalents for 9 years, with the latest figure at $1.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 62.0% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 62.0% YoY) and the FY2025 annual result came in at $2.0 million, down 47.97% from the prior year.
• Cash & Equivalents retreated to $1.2 million in Q1 2026 per ADXN's latest filing, from $2.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $16.1 million in Q1 2022 and troughed at $1.2 million in Q1 2026.
• A 5-year average of $5.5 million and a median of $4.2 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 69.17% in 2024, then soared 68.51% in 2025.
• Over 5 years, Cash & Equivalents stood at $7.2 million in 2022, then sank by 39.66% to $4.4 million in 2023, then fell by 12.46% to $3.8 million in 2024, then slumped by 46.26% to $2.1 million in 2025, then sank by 41.75% to $1.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.2 million, $2.1 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.